Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 1 Interventional

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

NCT00788684
View directory record Official record
Conditions
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
Interventions
rituximab, ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
4
States / cities
Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 27, 2026, 5:48 PM EDT
Active, not recruiting Phase 2 Interventional

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

NCT05994235
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Mosunetuzumab, Tazemetostat Pill
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00601926
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Paul Monk
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

NCT00959647
View directory record Official record
Conditions
Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
Interventions
Vismodegib, FOLFOX, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency

NCT00362063
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
growth hormone (Nutropin)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

NCT01781026
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00408070
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
UConn Health
Other
Eligibility
19 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01496742
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
32
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 27, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579
View directory record Official record
Conditions
Multiple Myeloma
Interventions
P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
23
States / cities
Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Not applicable Interventional

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab

NCT00287378
View directory record Official record
Conditions
Asthma, Allergy
Interventions
omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2009 · Synced Oct 27, 2026, 5:48 PM EDT
Not listed No phase listed Observational

Quality of Life After Stroke Using a Telemedicine-based Stroke Network

NCT02447094
View directory record Official record
Conditions
Stroke
Interventions
Alteplase
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

NCT00642746
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Erlotinib, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

NCT00402883
View directory record Official record
Conditions
Lung Cancer
Interventions
Bevacizumab, Pemetrexed, Radiotherapy, Folic Acid, vitamin B12, carboplatin
Drug · Procedure · Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Gainesville, Florida • Lakeland, Florida • Marietta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

NCT00320541
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine, paclitaxel, bevacizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
30
States / cities
Fayetteville, Arkansas • La Jolla, California • Mission Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 27, 2026, 5:48 PM EDT
Not listed Phase 2 Interventional

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936
View directory record Official record
Conditions
Presumed Ocular Histoplasmosis (POHS)
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Oct 27, 2026, 5:48 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

NCT01845844
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3mg/0.05cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

NCT00837330
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 0.3 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

NCT06734208
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Divarasib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 27, 2026, 5:48 PM EDT
Withdrawn Phase 2Phase 3 Interventional

The Use of Nutropin Depot in HIV-infected Adult Males

NCT00286676
View directory record Official record
Conditions
HIV Infection
Interventions
Nutropin, Oral Glucose Tolerance Test, Dual Energy X-ray Absorptiometry (DEXA), Computed Tomography (CT) Scan
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

NCT01700049
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
vismodegib (150 mg PO daily)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 27, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

NCT07049848
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Atezolizumab, Doxorubicin Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 5:48 PM EDT